The National Agency for Food and Drug Administration and Control has launched an upgraded version of its Med Safety App, a digital platform designed to enable healthcare professionals and members of the public to report suspected substandard and falsified medical products, as well as adverse drug reactions, quickly and securely.
NAFDAC said the launch marks a significant step in strengthening post-marketing surveillance and broadening public participation in safeguarding the quality, safety, and effectiveness of medicines in circulation.
The agency noted that substandard and falsified medicines remain a major public health challenge, contributing to treatment failure, prolonged illness, antimicrobial resistance, disability, and preventable deaths.
The improved platform features a more user-friendly interface, simplified reporting processes, enhanced data management capabilities, and the ability to upload photographs and relevant product information to support regulatory investigations.
Through the app, users can report suspicious medicines with altered expiry dates, questionable packaging, missing or fake NAFDAC registration numbers, poor product quality, and unexpected treatment failure, as well as adverse drug reactions including harmful responses to medical products.
NAFDAC said reports received through the app would support early detection of unsafe products, facilitate timely regulatory interventions, strengthen national medicine quality surveillance systems, and help remove harmful products from circulation.
The agency added that increased public engagement since the platform’s introduction had already contributed to faster identification of potential threats.
The agency urged healthcare professionals, pharmacists, physicians, nurses, patent and proprietary medicine vendors, community health workers, patients, caregivers, and the general public to download and actively use the app.
The Med Safety App is available on Android, iOS, web, and desktop platforms.
The press release was signed by NAFDAC Director-General and Chief Executive Officer, Prof. Mojisola Adeyeye, and dated 3 June, 2026.
